HOUSE MEDICAL TECHNOLOGY CAUCUS HEIGHTENS CONGRESSIONAL OVERSIGHT
This article was originally published in The Gray Sheet
Executive SummaryHOUSE MEDICAL TECHNOLOGY CAUCUS HEIGHTENS CONGRESSIONAL OVERSIGHT of FDA's medical device program. The establishment of the bipartisan caucus creates an additional congressional forum for review of FDA's medical device regulatory program and its effects on the medical device industry. The group, which currently has 17 members, was founded by Reps. Jim Ramstad (R-Minn.) and Tim Valentine (D-N.C.).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.